Glucose B.Braun Melsungen

Glucose B.Braun Melsungen is an intravenous solution for injection that contains glucose monohydrate as the active ingredient; the specific concentration is not disclosed. Manufactured by B. Braun Melsungen in the European Union, this sterile solution is classified as an excipient/solvent and is prescribed for fluid and electrolyte therapy. It is available only by prescription and is administered under medical supervision and used in hospital settings for patient care.

Glucose B.Braun Melsungen is indicated for several clinical situations where rapid elevation of plasma glucose or fluid replacement is required.

- Treatment of hypoglycemia in patients unable to take oral glucose. - Fluid and electrolyte replacement during dehydration or surgery. - Component of parenteral nutrition regimens to provide an energy source. - Support for patients receiving intravenous medications that may lower blood glucose. - Management of electrolyte imbalances when combined with appropriate salts.

Intravenous administration of glucose solution may be associated with a range of adverse reactions, most of which are mild and transient.

Common: - Mild hyperglycemia or transient rise in blood glucose. - Local irritation or pain at the injection site. - Nausea or mild vomiting. - Headache or dizziness.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Electrolyte disturbances such as hyponatremia. - Allergic reactions including rash, urticaria, or anaphylaxis. - Volume overload in patients with cardiac or renal impairment.

Glucose B.Braun Melsungen should be used with caution in specific patient populations and clinical conditions.

- Assess blood glucose levels before and during infusion to avoid hyperglycemia. - Adjust infusion rate in patients with renal or cardiac failure to prevent fluid overload. - Use reduced concentrations in neonates and pediatric patients. - Avoid use in patients with known hypersensitivity to glucose solutions. - Monitor electrolyte balance, especially sodium and potassium, during prolonged therapy. - Consider compatibility with other intravenous drugs before co‑administration.

Glucose solutions can interact with other intravenous agents, affecting their efficacy or safety.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Simultaneous infusion of potassium chloride in concentrations that may precipitate. - Mixing with calcium‑containing solutions that can cause precipitation.

Use with caution: - Concurrent use of diuretics that may alter fluid and electrolyte status. - Administration alongside beta‑blockers, which can mask signs of hypoglycemia. - Use with other hyperosmolar solutions, requiring careful monitoring of osmolarity.